[HTML] sciencedirect.com

[HTML][HTML] Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

ML Schubert, M Schmitt, L Wang, CA Ramos… - Annals of oncology, 2021 - Elsevier
Highlights•CAR T cells are associated with unique side-effects.•Cytokine release syndrome
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …
被引用次数：364 相关文章

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

ML Schubert, M Schmitt, L Wang… - Annals of oncology …, 2021 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T cells directed against the B-cell marker CD19 are
currently changing the landscape for treatment of patients with refractory and/or relapsed B …

[引用][C] Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

ML Schubert, M Schmitt, L Wang, CA Ramos… - Annals of …, 2021 - cir.nii.ac.jp
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.

ML Schubert, M Schmitt, L Wang… - Annals of Oncology …, 2020 - europepmc.org
Chimeric antigen receptor (CAR) T cells directed against the B-cell marker CD19 are
currently changing the landscape for treatment of patients with refractory and/or relapsed B …

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

ML Schubert, M Schmitt, L Wang… - Annals of …, 2021 - annalsofoncology.org
Chimeric antigen receptor (CAR) T cells directed against the B-cell marker CD19 are
currently changing the landscape for treatment of patients with refractory and/or relapsed B …